Currently, GPx3 is considered a new tumor-suppressor gene [23], and its hypermethylation, which is associated with the further down-regulation of GPx3, was observed in patients with Barretts esophagus [54], endometrial adenocarcinoma [55] and prostate cancer [56]
Weight Loss Results From Injectable Trials The SURMOUNT trial program tested injectable tirzepatide (5, 10, and 15 mg weekly) in people with obesity
Biotin injections may be ideal for people with thinning hair, weak nails, low dietary intake, increased B vitamin demand, or realistic wellness goals
Bridging boundaries: making drug repurposing the new normal brings together key insights from the International Drug Repurposing Conferences (iDR) 2024 and 2025, highlighting both the challenges and opportunities in unlocking the full potential of drug repurposing